The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.
Johnson & Johnson’s JNJ MedTech unit has temporarily paused sales of Varipulse, its pulsed field ablation (PFA) therapy to ...
The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.
Johnson & Johnson announced that on January 5, “out of an abundance of caution,” Johnson & Johnson MedTech temporarily paused the U.S.
In 2024, we saw another proactive year for some of the biggest names in medtech as they looked to bolster their ranks through ...
After a busy 2024, experts called out competition in soft tissue robotics, uncertainty from a Trump White House and continued ...
Bernstein lowered the firm’s price target on Johnson & Johnson to $160 from $177 and keeps a Market Perform rating on the shares as part of ...
We came across a bullish thesis on Johnson & Johnson (NYSE:JNJ) on Business Model Mastery Substack by The Antifragile ...
Biologics License Application acceptance supported by results from the Phase 3 Vivacity-MG3 study Results demonstrate sustained disease control over 24 weeks in a broad ...